These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38694152)

  • 1. The Psychiatrist's Role in Treating Perinatal Opioid Use Disorder and Reducing Maternal Mortality.
    Witcraft SM; Johnson C; Guille C
    Focus (Am Psychiatr Publ); 2024 Jan; 22(1):25-34. PubMed ID: 38694152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addressing buprenorphine bottlenecks in the context of MAT Act implementation: A shared responsibility.
    Ostrach B; Hill L; Carpenter D; Pollini R
    J Am Pharm Assoc (2003); 2023; 63(4):1044-1048. PubMed ID: 37149144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eliminate the buprenorphine DEA X waiver: Justification using a policy analysis approach.
    Jones KF; O'Reilly Jacob M; Spetz J; Hailer L; Tierney M
    J Nurs Scholarsh; 2023 May; 55(3):655-664. PubMed ID: 36624606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methadone and buprenorphine discontinuation among postpartum women with opioid use disorder.
    Schiff DM; Nielsen TC; Hoeppner BB; Terplan M; Hadland SE; Bernson D; Greenfield SF; Bernstein J; Bharel M; Reddy J; Taveras EM; Kelly JF; Wilens TE
    Am J Obstet Gynecol; 2021 Oct; 225(4):424.e1-424.e12. PubMed ID: 33845029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Buprenorphine/naloxone and methadone effectiveness for reducing craving in individuals with prescription opioid use disorder: Exploratory results from an open-label, pragmatic randomized controlled trial.
    McAnulty C; Bastien G; Eugenia Socias M; Bruneau J; Foll BL; Lim R; Brissette S; Ledjiar O; Marsan S; Talbot A; Jutras-Aswad D;
    Drug Alcohol Depend; 2022 Oct; 239():109604. PubMed ID: 36037586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are North Carolina clinicians delivering opioid use disorder treatment to Medicaid beneficiaries?
    Grove LR; Rao N; Domino ME
    Addiction; 2022 Nov; 117(11):2855-2863. PubMed ID: 35194878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Buprenorphine/Naloxone and Methadone on Depressive Symptoms in People with Prescription Opioid Use Disorder: A Pragmatic Randomised Controlled Trial.
    Bastien G; McAnulty C; Ledjiar O; Socias ME; Le Foll B; Lim R; Hassan AN; Brissette S; Marsan S; Talbot A; Jutras-Aswad D;
    Can J Psychiatry; 2023 Aug; 68(8):572-585. PubMed ID: 36519188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations Between Buprenorphine\Naloxone and Methadone Treatment and non-Opioid Substance Use in Prescription-Type Opioid Use Disorder: Secondary Analyses From the OPTIMA Study: Associations entre le traitement avec la buprénorphine/naloxone et avec la méthadone et l'utilisation de substances non opioïdes dans le trouble lié à l'usage d'opioïdes de type sur ordonnance : analyses secondaires de l'étude OPTIMA.
    Bakouni H; Sharafi H; Drouin S; Fortin R; Marsan S; Brissette S; Socias ME; Le Foll B; Lim R; Jutras-Aswad D
    Can J Psychiatry; 2024 Apr; 69(4):252-263. PubMed ID: 37899716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of naltrexone in treating opioid use disorder in pregnancy.
    Towers CV; Katz E; Weitz B; Visconti K
    Am J Obstet Gynecol; 2020 Jan; 222(1):83.e1-83.e8. PubMed ID: 31376396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Geographic and specialty distribution of US physicians trained to treat opioid use disorder.
    Rosenblatt RA; Andrilla CH; Catlin M; Larson EH
    Ann Fam Med; 2015; 13(1):23-6. PubMed ID: 25583888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States.
    Jaffe JH; O'Keeffe C
    Drug Alcohol Depend; 2003 May; 70(2 Suppl):S3-11. PubMed ID: 12738346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medications for management of opioid use disorder.
    Koehl JL; Zimmerman DE; Bridgeman PJ
    Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in buprenorphine prescribing readiness among primary care professionals with and without X-waiver training in the US.
    Franz B; Dhanani LY; Hall OT; Brook DL; Simon JE; Miller WC
    Harm Reduct J; 2023 Dec; 20(1):180. PubMed ID: 38129903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opioid agonist therapy switching among individuals with prescription-type opioid use disorder: Secondary analysis of a pragmatic randomized trial.
    Mocanu V; Bozinoff N; Wood E; Jutras-Aswad D; Le Foll B; Lim R; Cheol Choi J; Yin Mok W; Eugenia Socias M;
    Drug Alcohol Depend; 2023 Jul; 248():109932. PubMed ID: 37224674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac and mortality outcome differences between methadone, buprenorphine and naltrexone prescriptions in patients with an opioid use disorder.
    Wang L; Volkow ND; Berger NA; Davis PB; Kaelber DC; Xu R
    J Clin Psychol; 2023 Dec; 79(12):2869-2883. PubMed ID: 37584532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What the X? Understanding changes in buprenorphine prescribing regulation.
    Speight C
    J Am Assoc Nurse Pract; 2024 Mar; 36(3):147-150. PubMed ID: 37646580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services.
    Krawczyk N; Mojtabai R; Stuart EA; Fingerhood M; Agus D; Lyons BC; Weiner JP; Saloner B
    Addiction; 2020 Sep; 115(9):1683-1694. PubMed ID: 32096302
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.